Figure 8.

The capacity of anti-DDV immune sera to confer protection against lethal DENV2 challenge in AG129 mice

(A) Schematic representation of the experimental design. Groups of AG129 mice were administered (intraperitoneally [i.p.]) BALB/c immune sera in two dosage levels, 100 (n = 4/group) and 300 (n = 6/group) μL per mouse. The pVAX1 group of animals received a 300 μL dosage (n = 3/group). Two hours after passive transfer, the mice were challenged with a lethal dose of DENV2 (105 FIU/mouse; n = 7/group). (B–D) All groups were monitored for body-weight changes (B), clinical symptoms (C), and survival (D). Data are representative of three independent experiments. Values are depicted are mean ± SD. The study design schematic diagram was created with BioRender.com.